A Double-Blind Placebo-Controlled study of the efficacy and safety of the p38 Map kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma.
- Year: 2009
- Type: Pharmaceutical - Pain
- Phase: II
- Indication: Neuropathic Pain
Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.